How to Take a GLP-1 Pill: Rybelsus, the Wegovy Pill and Foundayo Compared

There are now two completely different kinds of GLP-1 pill on the US market, and they are not taken the same way at all.

Oral semaglutide — sold as Rybelsus, as Ozempic tablets and as the Wegovy pill — has one of the most demanding administration routines of any common medication. Empty stomach. Morning. Four ounces of water and nothing else. Then thirty minutes of nothing at all.

Foundayo (orforglipron), approved April 1, 2026, has none of that. With or without food. Any time of day. No water restriction [3][6].

If you are switching between them, or choosing between them, the difference in daily routine is larger than the difference in any other feature. Here is what each label actually requires.

This article summarizes the FDA-approved prescribing information and Medication Guides for these products. It is a description of those documents, not instruction from us and not medical advice. Follow the prescription you were given and the Medication Guide in your own bottle, and take any question about your dose, your timing or a switch between products to your prescriber or pharmacist.

How does the label say to take oral semaglutide?

The instruction is identical across Rybelsus, Ozempic tablets and Wegovy tablets. Section 2.1 of the Rybelsus and Ozempic tablets label says [1]:

“Take one RYBELSUS or OZEMPIC tablet orally once daily on an empty stomach in the morning with water (up to 4 ounces of water). Do not take RYBELSUS or OZEMPIC tablets with other liquids besides water.”

“Do not take more than one tablet per day.”

“Swallow tablets whole. Do not split, crush, chew or dissolve in any solution.”

“After taking RYBELSUS or OZEMPIC tablets, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications.”

The Wegovy tablet section says the same thing in its own words, and the Medication Guide gives the patient-facing version [2]:

“Take 1 WEGOVY tablet by mouth on an empty stomach in the morning with water (no more than 4 ounces). Do not take WEGOVY tablets with any other liquids besides water.”

“Do not split, crush, chew or dissolve WEGOVY tablets. Swallow WEGOVY tablets whole.”

“After 30 minutes, you can eat, drink, or take other oral medicines.”

So, in order: wake up, take the tablet with up to 4 ounces of water, wait 30 minutes, then everything else — including your coffee, your other medications and your breakfast.

Why does it have to be on an empty stomach?

Because unlike an injection, an oral peptide has to survive the stomach and get absorbed there, and that only works under narrow conditions.

The label itself gives a window into how the 30-minute figure was established. In a pharmacokinetic study described in section 12.3, healthy subjects took semaglutide tablets once daily for 10 days “with 50 mL or 120 mL of water under fasting conditions with post-dose fasting period of 15, 30, 60 or 120 minutes” [1].

Two useful things come out of that.

More water does not help, and past a point it actively hurts. Within the label’s permitted range the volume does not matter: the label reports “no clinically significant differences in semaglutide absorption with administration of 50 mL or 120 mL of water” [1][2].

But the same section describes a second study that went above the permitted range, and there the difference was real. Single doses were given with 50 mL or 240 mL of water after an overnight fast, and the label reports that “semaglutide absorption [i.e., area under the curve (AUC) and peak concentrations (Cmax)] was higher following dosing with 50 mL water compared to that of 240 mL water” [1].

So the “up to 4 ounces” instruction — roughly 120 mL — is a ceiling with evidence behind it, not a rounded guess. Washing the tablet down with a full 8-ounce glass is outside the label instruction, and the label’s own pharmacokinetic data indicate it lowers absorption rather than leaving it unchanged. This is the rare case where doing more than the instructions say gets you less of the drug.

The waiting period is doing real work. The study varied the post-dose fasting period specifically, and the label landed on “at least 30 minutes.” That is why the instruction is worded as a minimum rather than a suggestion.

What is different about Foundayo?

Almost everything about the routine.

Foundayo (orforglipron) is a small-molecule, non-peptide GLP-1 receptor agonist, which is a chemical distinction with a practical consequence: it does not need the absorption conditions a peptide does. The label’s administration section is three lines [3]:

“Take FOUNDAYO orally once daily, with or without food.”

“Swallow tablets whole. Do not break, crush, or chew.”

“Do not take more than one tablet per day.”

That is it. No fasting window, no water rule, no 30-minute wait, no specified time of day. Lilly’s consumer page describes it as “once daily on your schedule — with or without food, and without water restrictions” [5], and the launch announcement made the same point [6].

The one thing both share: swallow whole. Every oral GLP-1 label forbids splitting, crushing or chewing.

How do the dose schedules compare?

	Oral semaglutide (Wegovy tablets)	Foundayo (orforglipron)
Starting dose	1.5 mg once daily, days 1–30	0.8 mg once daily, at least 30 days
Step 2	4 mg, days 31–60	2.5 mg, at least 30 days
Step 3	9 mg, days 61–90	5.5 mg, at least 30 days
Step 4	25 mg maintenance, day 91 onward	9 mg, at least 30 days
Further steps	—	14.5 mg, then 17.2 mg maximum
Timing	Empty stomach, morning, 4 oz water, 30-min wait	Any time, with or without food

Sources: the Wegovy [2] and Foundayo [3] labels.

Both escalate in roughly monthly steps, but the Foundayo label distinguishes between them. The first two increases are written flatly — after at least 30 days on 0.8 mg, increase to 2.5 mg; after at least 30 days on 2.5 mg, increase to 5.5 mg. From there the wording turns conditional: the dosage “may be increased to the next dosage level (9 mg, 14.5 mg, or 17.2 mg once daily) after at least 30 days on the current dosage, based on treatment response and tolerability.” The maximum is 17.2 mg once daily [3].

In other words, 5.5 mg is the first point at which the label treats stopping as a normal outcome rather than a step on the way up. Where you land is a prescriber’s judgment, not a default.

Neither of those schedules is something to implement on your own. Dose changes come from your prescriber.

What happens if you miss a dose?

The two families give opposite answers, and this follows directly from the administration rules.

Oral semaglutide: “If a dose is missed, skip the missed dose and take the next dose the following day” [1]. The Wegovy tablet section says the same [2].

There is no catch-up, and the reason is built into the rest of the label. A “catch-up” tablet in the afternoon could not meet the empty-stomach, morning, 30-minute conditions the drug needs, so the label does not offer one.

Foundayo: “If a dose is missed, instruct patients to take the dose as soon as possible,” and “advise patients not to double up the next dose” [3]. The Medication Guide: “If you miss a dose, take it as soon as possible. Do not take 2 doses of FOUNDAYO in the same day” [4].

Because Foundayo has no timing conditions, a missed dose can simply be taken when remembered.

One more Foundayo rule: “If 7 or more consecutive doses are missed, reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions” [3]. The patient version tells you to call your provider about how to restart [4]. Oral semaglutide carries no equivalent instruction.

How do you store the pills?

Neither needs a refrigerator, which is the headline advantage over the injections for anyone who travels. But each has a storage condition people miss.

Oral semaglutide. Store at 20 to 25 °C (68 to 77 °F), excursions permitted to 15 to 30 °C (59 to 86 °F). Then the part that matters: “Store and dispense WEGOVY tablets in the original bottle. Store WEGOVY tablet in the original bottle until use to protect tablets from moisture. Store WEGOVY tablets in a dry place away from moisture” [2].

That rules out a weekly pill organizer, and it rules out a bathroom cabinet. The tablets stay in the bottle they came in, wherever you put them.

Foundayo. Same temperature range, plus a light instruction: “FOUNDAYO is light sensitive. Protect from light by keeping in the original bottle and carton and replacing the cap each time after opening. If the carton is no longer available, store bottle away from light” [3]. Bottles come with a desiccant and a child-resistant closure.

Both come as bottles of 30 tablets, one month per bottle.

Does Foundayo interact with anything I should know about?

Two label items are worth flagging because they are easy to miss and both have real-world consequences.

Oral hormonal contraceptives. The Foundayo label advises “patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 30 days after initiation with FOUNDAYO and for 30 days after each dose escalation.” The reason given is that Foundayo delays gastric emptying and so has the potential to affect absorption of oral medicines taken at the same time. It adds: “Hormonal contraceptives that are not administered orally should not be affected” [3].

Note the wording: 30 days after starting and 30 days after each escalation step. With six dose levels, that is a recurring instruction, not a one-time one.

CYP3A4 interactions. The label says to avoid strong CYP3A4 inhibitors that also inhibit OATP1B, and that “the maximum dosage of Foundayo is 9 mg once daily when used concomitantly with a strong CYP3A4 inhibitor.” Strong CYP3A4 inducers should be avoided, and effectiveness should be monitored with moderate inducers [3].

Bring a full medication list, including over-the-counter products, to the appointment where this is prescribed.

Oral semaglutide’s counterpart concern is the 30-minute rule itself: because it says to wait at least 30 minutes before taking other oral medications, everything else in your morning routine has to move [1][2].

What are the practical trade-offs?

Setting aside effectiveness, which our results coverage handles, the daily-life differences come down to this:

Oral semaglutide asks more of your morning. Thirty minutes of nothing is not difficult in principle and is genuinely annoying in practice — before coffee, before breakfast, before your other pills. People who wake up and immediately eat, or who take several morning medications, will feel it. Shift workers and frequent travelers have the hardest version of the problem, because “morning” has to be a real morning.

Foundayo asks nothing of your schedule but is easier to forget. A tablet you can take at any time is a tablet with no natural anchor. It is also daily, so there are 30 chances a month to miss one rather than four.

Both beat injections on travel. No refrigerator, no in-use day count, no cooling case, no sharps container, no declaring liquids at a TSA checkpoint. For anyone whose main friction with a GLP-1 is logistics rather than effect, that is the whole argument.

Whether any of that makes one right for you is a conversation with a prescriber, not a decision to make from a comparison table.

The short version

• Rybelsus, Ozempic tablets, Wegovy pill: empty stomach, morning, up to 4 oz of water only, swallow whole, then wait at least 30 minutes before food, drink or other pills. Miss one, skip it.
• Foundayo: any time, with or without food, swallow whole. Miss one, take it when you remember, never two in a day. Seven days in a row missed means calling your provider.
• Neither needs refrigeration. Oral semaglutide stays in its bottle for moisture. Foundayo stays in its bottle and carton for light.
• None of them may be split, crushed or chewed.

Sources

1. Novo Nordisk. RYBELSUS and OZEMPIC tablets (semaglutide) — US Prescribing Information, Section 2.1 and Section 12.3, and Medication Guide. https://www.novo-pi.com/ozempic.pdf
2. Novo Nordisk. WEGOVY (semaglutide) injection and WEGOVY (semaglutide) tablets — US Prescribing Information, Sections 2.1, 2.3, 2.4 and 16, and Medication Guide, June 2026. https://www.novo-pi.com/wegovy.pdf
3. US Food and Drug Administration / Eli Lilly and Company. FOUNDAYO (orforglipron) tablets — US Prescribing Information, Sections 2.1, 2.2, 2.3, 7.3, 8.3 and 16.2, April 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf
4. Eli Lilly and Company. Medication Guide — FOUNDAYO (orforglipron) tablets, July 2026. https://pi.lilly.com/us/foundayo-us-mg.pdf?s=mg
5. Eli Lilly and Company. How to Take Foundayo (orforglipron): Dosing, Storage & More. https://foundayo.lilly.com/how-to-take
6. Eli Lilly and Company. “Foundayo (orforglipron), Lilly’s new oral GLP-1 pill for weight loss, now available in the U.S.,” PR Newswire, April 9, 2026. https://www.prnewswire.com/news-releases/foundayo-orforglipron-lillys-new-oral-glp-1-pill-for-weight-loss-now-available-in-the-us-302737538.html